Jack Hirsh

Q: What Schools Are Affiliated With Jack Hirsh

Jack Hirsh is affiliated with the following schools: University of Amsterdam, University at Buffalo, University of Melbourne, McMaster University, All India Institute of Medical Sciences, New Delhi, Stanford University, University of Toronto, Texas A&M University

Jack Hirsh's AcademicInfluence.com Rankings

Jack Hirsh

Biology

#1801

World Rank

#2921

Historical Rank

Neuroscience

#140

World Rank

#148

Historical Rank

biology Degrees

Jack Hirsh

Philosophy

#1787

World Rank

#3189

Historical Rank

Logic

#321

World Rank

#642

Historical Rank

philosophy Degrees

Download Badge

Biology
Philosophy

Jack Hirsh's Degrees

Doctorate Medicine Stanford University

Why Is Jack Hirsh Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Jack Hirsh is a Canadian clinician and scientist specializing in anticoagulant therapy and thrombosis. Born in Melbourne, Australia, Hirsh is a graduate of the University of Melbourne Medical School. He studied hematology at Washington University in St. Louis, the London Postgraduate Medical School and the University of Toronto. In 1973 he joined the Faculty of Medicine of McMaster University. He is also the Director of the Hamilton Civic Hospital Research Centre.

(See a Problem?)

Jack Hirsh's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Evidence-based medicine. A new approach to teaching the practice of medicine. (1992) (4005)
Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. (1995) (2216)
Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). (2008) (2191)
Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. (2001) (1632)
The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. (2004) (1585)
Derivation of a Simple Clinical Model to Categorize Patients Probability of Pulmonary Embolism: Increasing the Models Utility with the SimpliRED D-dimer (2000) (1517)
Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. (2001) (1444)
Hemorrhagic complications of anticoagulant treatment. (1992) (1263)
Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. (1990) (1216)
A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. (1996) (1191)
A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. (1999) (1125)
Aspirin-Resistant Thromboxane Biosynthesis and the Risk of Myocardial Infarction, Stroke, or Cardiovascular Death in Patients at High Risk for Cardiovascular Events (2002) (1027)
Platelet-active drugs: the relationships among dose, effectiveness, and side effects. (2004) (1008)
Use of a Clinical Model for Safe Management of Patients with Suspected Pulmonary Embolism (1998) (995)
Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. (2004) (931)
Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. (1998) (851)
A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. (2003) (849)
American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. (2003) (830)
Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). (2008) (796)
Management of anticoagulation before and after elective surgery. (1997) (779)
Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). (2008) (748)
Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. (1986) (747)
Accuracy of clinical assessment of deep-vein thrombosis (1995) (738)
Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. (1982) (727)
Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). (2008) (725)
Low Molecular Weight Heparin (1993) (699)
Use of antithrombotic agents during pregnancy. (1992) (672)
A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. (1972) (631)
Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. (1979) (605)
Managing oral anticoagulant therapy. (2001) (603)
Drug therapy : heparin (1991) (594)
Oral anticoagulant drugs. (1991) (593)
Management of deep vein thrombosis and pulmonary embolism. A statement for healthcare professionals. Council on Thrombosis (in consultation with the Council on Cardiovascular Radiology), American Heart Association. (1996) (588)
Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. (2010) (545)
A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. (1986) (537)
A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. (1993) (526)
Interactions of Warfarin with Drugs and Food (1994) (513)
Use of antithrombotic agents during pregnancy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. (2004) (512)
Pulmonary angiography, ventilation lung scanning, and venography for clinically suspected pulmonary embolism with abnormal perfusion lung scan. (1983) (495)
Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. (1990) (486)
Double-blind randomised trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer (1994) (483)
Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (2014) (471)
Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. (1992) (466)
Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis. (1995) (447)
Guide to Anticoagulant Therapy: Heparin: A Statement for Healthcare Professionals From the American Heart Association (2001) (441)
The Role of Venous Ultrasonography in the Diagnosis of Suspected Deep Venous Thrombosis and Pulmonary Embolism (1998) (441)
The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy (2004) (434)
The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. (1988) (430)
Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. (2004) (419)
Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. (2004) (416)
Small subcutaneous doses of heparin in prevention of venous thrombosis. (1973) (412)
Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. (2012) (410)
Effect of a Preoperative Intervention on Preoperative and Postoperative Outcomes in Low-Risk Patients Awaiting Elective Coronary Artery Bypass Graft Surgery (2000) (395)
Platelet-active drugs : the relationships among dose, effectiveness, and side effects. (2004) (390)
Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. (1982) (387)
Optimal Duration of Oral Anticoagulant Therapy: A Randomized Trial Comparing Four Weeks with Three Months of Warfarin in Patients with Proximal Deep Vein Thrombosis (1995) (383)
Antiphospholipid antibodies and venous thromboembolism. (1995) (381)
A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. (1994) (370)
Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. (1996) (370)
The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits. (1982) (367)
Comparison of 5-mg and 10-mg Loading Doses in Initiation of Warfarin Therapy (1997) (350)
A standard heparin nomogram for the management of heparin therapy. (1991) (341)
Executive summary: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). (2008) (340)
Diagnostic efficacy of impedance plethysmography for clinically suspected deep-vein thrombosis. A randomized trial. (2020) (339)
Accuracy of Ultrasound for the Diagnosis of Deep Venous Thrombosis in Asymptomatic Patients after Orthopedic Surgery (1995) (339)
Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants’ data from seven trials (2011) (328)
Safety of withholding heparin in pregnant women with a history of venous thromboembolism. Recurrence of Clot in This Pregnancy Study Group. (2000) (328)
Medical device‐induced thrombosis: what causes it and how can we prevent it? (2015) (327)
Establishing a Therapeutic Range for Heparin Therapy (1993) (318)
Comparison of high-dose with low-dose subcutaneous heparin to prevent left ventricular mural thrombosis in patients with acute transmural anterior myocardial infarction. (1989) (318)
An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. (2003) (317)
Distribution of thrombosis in patients with symptomatic deep vein thrombosis. Implications for simplifying the diagnostic process with compression ultrasound. (1993) (314)
Antithrombotic and thrombolytic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). (2008) (312)
Prevention of deep vein thrombosis after elective hip surgery. A randomized trial comparing low molecular weight heparin with standard unfractionated heparin. (1991) (310)
Clinical Validity of a Negative Venogram in Patients with Clinically Suspected Venous Thrombosis (1981) (307)
Diagnostic value of ventilation-perfusion lung scanning in patients with suspected pulmonary embolism. (1985) (307)
Antithrombotic agents in coronary artery disease. (1989) (306)
New antithrombotic drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). (2008) (301)
A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism. (1990) (298)
The Vexing Problem of Guidelines and Conflict of Interest: A Potential Solution (2010) (297)
Heparin Kinetics in Venous Thrombosis and Pulmonary Embolism (1976) (291)
RANDOMISED COMPARISON OF TWO INTENSITIES OF ORAL ANTICOAGULANT THERAPY AFTER TISSUE HEART VALVE REPLACEMENT (1988) (281)
Impedance Plethysmography Using the Occlusive Cuff Technique in the Diagnosis of Venous Thrombosis (1976) (279)
Prevention and treatment of postphlebitic syndrome: results of a 3-part study. (2001) (276)
Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. (2012) (257)
Heparin Binding to Plasma Proteins, an Important Mechanism for Heparin Resistance (1992) (251)
Sensitivity and Specificity of a Rapid Whole-Blood Assay for D-Dimer in the Diagnosis of Pulmonary Embolism (1998) (247)
A Comparison of the Safety and Efficacy of Oral Antiocoagulation for the Treatment of Venous Thromboembolic Disease in Patients with or without Malignancy (2000) (244)
Effect of Short-Term vs. Long-Term Blood Storage on Mortality after Transfusion. (2016) (239)
Characterization of the stress-inducing effects of homocysteine. (1998) (237)
A novel and rapid whole-blood assay for D-dimer in patients with clinically suspected deep vein thrombosis. (1995) (235)
Graduated compression stockings in the prevention of postoperative venous thromboembolism. A meta-analysis. (1994) (234)
Hemorrhagic complications of anticoagulant treatment. (2004) (231)
AHA/ACC Scientific StatementAmerican Heart Association/American College of Cardiology Foundation guide to warfarin therapy1 (2003) (231)
A randomized trial of less intense postoperative warfarin or aspirin therapy in the prevention of venous thromboembolism after surgery for fractured hip. (1989) (224)
Beyond Unfractionated Heparin and Warfarin: Current and Future Advances (2007) (223)
Assessment of outpatient treatment of deep-vein thrombosis with low-molecular-weight heparin. (1998) (214)
Management of Suspected Deep Venous Thrombosis in Outpatients by Using Clinical Assessment and d-dimer Testing (2001) (213)
Mechanism of action and pharmacology of unfractionated heparin. (2001) (213)
Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. (1998) (213)
DOUBLE-BLIND RANDOMISED TRIAL OF ORG 10172 LOW-MOLECULAR-WEIGHT HEPARINOID IN PREVENTION OF DEEP-VEIN THROMBOSIS IN THROMBOTIC STROKE (1987) (210)
The Relationship between Anti-Factor Xa Level and Clinical Outcome in Patients Receiving Enoxaparine Low Molecular Weight Heparin to Prevent Deep Vein Thrombosis after Hip Replacement (1989) (208)
Guide to anticoagulant therapy. Part 1: Heparin. American Heart Association. (1994) (208)
American Association of Orthopedic Surgeons and American College of Chest Physicians guidelines for venous thromboembolism prevention in hip and knee arthroplasty differ: what are the implications for clinicians and patients? (2009) (208)
Treatment of heparin-induced thrombocytopenia: a critical review. (2004) (205)
Guide to anticoagulant therapy. Part 2: Oral anticoagulants. American Heart Association. (1994) (200)
The incidence of symptomatic venous thromboembolism during and after prophylaxis with enoxaparin: a multi-institutional cohort study of patients who underwent hip or knee arthroplasty. Canadian Collaborative Group. (1998) (200)
Risks to the Fetus of Anticoagulant Therapy During Pregnancy (1989) (197)
A comparison of the antithrombotic and haemorrhagic effects of low molecular weight heparin fractions: the influence of the method of preparation. (1984) (195)
How we diagnose and treat deep vein thrombosis. (2002) (195)
Low molecular weight heparin: a critical analysis of clinical trials. (1994) (194)
Hemorrhagic complications of long-term anticoagulant therapy. (1989) (194)
A randomized trial comparing 5-mg and 10-mg warfarin loading doses. (1999) (191)
Heparin therapy during pregnancy. Risks to the fetus and mother. (1989) (190)
Relationship between the anticoagulant and antithrombotic effects of heparin in experimental venous thrombosis. (1977) (190)
Thrombogenic effect of high-dose aspirin in rabbits. Relationship to inhibition of vessel wall synthesis of prostaglandin I2-like activity. (1978) (186)
The international normalized ratio. A guide to understanding and correcting its problems. (1994) (185)
Combined use of leg scanning and impedance plethysmography in suspected venous thrombosis. An alternative to venography. (1977) (185)
Thrombolytic therapy for pulmonary embolism: is it effective? Is it safe? When is it indicated? (1997) (181)
Heparin and low-molecular weight heparins (1992) (180)
The sixth (2000) ACCP guidelines for antithrombotic therapy for prevention and treatment of thrombosis. American College of Chest Physicians. (2001) (179)
Risks to the Fetus of Radiologic Procedures Used in the Diagnosis of Maternal Venous Thromboembolic Disease (1989) (179)
Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomised controlled trial (2000) (178)
Cost effectiveness of clinical diagnosis, venography, and noninvasive testing in patients with symptomatic deep-vein thrombosis. (1981) (175)
A histomorphometric comparison of the effects of heparin and low-molecular-weight heparin on cancellous bone in rats. (1997) (173)
Prevention of deep vein thrombosis in potential neurosurgical patients. A randomized trial comparing graduated compression stockings alone or graduated compression stockings plus intermittent pneumatic compression with control. (1989) (173)
Ex-Vivo and In-Vitro Evidence that Low Molecular Weight Heparins Exhibit Less Binding to Plasma Proteins than Unfractionated Heparin (1994) (173)
Adjusted subcutaneous heparin or continuous intravenous heparin in patients with acute deep vein thrombosis. A randomized trial. (1987) (173)
Hemorrhagic complications of anticoagulant therapy. (1986) (171)
Optimal therapeutic range for oral anticoagulants. (1989) (168)
Effect of aspirin on mortality in the primary prevention of cardiovascular disease. (2011) (167)
Comparison of Fixed-Dose Weight-Adjusted Unfractionated Heparin and Low-Molecular- Weight Heparin for Acute Treatment of Venous Thromboembolism (2006) (166)
Congenital antithrombin III deficiency. Incidence and clinical features. (1989) (164)
Approach to outcome measurement in the prevention of thrombosis in surgical and medical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. (2012) (163)
Bleeding associated with antithrombotic therapy. (1980) (163)
Prevention of venous thrombosis in patients with intracranial disease by intermittent pneumatic compression of the calf (1977) (162)
Oral anticoagulation treatment in the elderly: a nested, prospective, case-control study. (2000) (162)
Fish oils and low-molecular-weight heparin for the reduction of restenosis after percutaneous transluminal coronary angioplasty. The EMPAR Study. (1996) (161)
The effects of low molecular weight and standard heparin on calcium loss from fetal rat calvaria. (1995) (160)
Replacement of venography in suspected venous thrombosis by impedance plethysmography and 125I-fibrinogen leg scanning: a less invasive approach. (2020) (158)
Platelet-Active Drugs (1998) (156)
Monitoring unfractionated heparin with the aPTT: Time for a fresh look (2006) (155)
Efficacy and Cost of Low-Molecular-Weight Heparin Compared with Standard Heparin for the Prevention of Deep Vein Thrombosis after Total Hip Arthroplasty (1993) (150)
Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor (2004) (150)
New anticoagulant drugs: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. (2004) (148)
The effect of platelet age on platelet adherence to collagen. (1968) (148)
Venous Thromboembolism , Thrombophilia , Antithrombotic Therapy , and Pregnancy (2008) (148)
Evaluation of a portable prothrombin time monitor for home use by patients who require long-term oral anticoagulant therapy. (1993) (148)
Hemorrhagic doses of heparin and other glycosaminoglycans induce a platelet defect. (1986) (147)
Ardeparin Sodium for Extended Out-of-Hospital Prophylaxis against Venous Thromboembolism after Total Hip or Knee Replacement (2000) (146)
Postthrombotic syndrome after hip or knee arthroplasty: a cross-sectional study. (2000) (145)
THE DEVELOPMENT OF UROKINASE AS A THROMBOLYTIC AGENT. MAINTENANCE OF A SUSTAINED THROMBOLYTIC STATE IN MAN BY ITS INTRAVENOUS INFUSION. (1965) (145)
Effectiveness of intermittent pulsatile elastic stockings for the prevention of calf and thigh vein thrombosis in patients undergoing elective knee surgery. (1979) (145)
Is impaired renal function a contraindication to the use of low-molecular-weight heparin? (2002) (144)
Histomorphometric analysis of the effects of standard heparin on trabecular bone in vivo. (1996) (144)
Neonatal coagulation defect due to anticonvulsant drug treatment in pregnancy (1970) (142)
TUMORS, MUCUS PRODUCTION, AND HYPERCOAGULABILITY (1974) (142)
In Vitro and in Vivo Functions of Thrombin-Treated Platelets (1976) (141)
Comparative benefits of clopidogrel and aspirin in high-risk patient populations: lessons from the CAPRIE and CURE studies. (2004) (137)
A critical review of the evidence supporting a relationship between impaired fibrinolytic activity and venous thromboembolism. (1991) (137)
Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. (1995) (136)
Prevention of venous thrombosis with small, subcutaneous doses of heparin. (1976) (136)
Temporal trends in prevention of venous thromboembolism following primary total hip or knee arthroplasty 1996-2001: findings from the Hip and Knee Registry. (2003) (136)
A simple clinical model for the diagnosis of deep‐vein thrombosis combined with impedance plethysmography: potential for an improvement in the diagnostic process (1998) (135)
A Comparison of General Anesthesia and Regional Anesthesia as a Risk Factor for Deep Vein Thrombosis Following Hip Surgery: A Critical Review (1990) (135)
Arteriovenous-shunt thrombosis. Prevention by sulfinpyrazone. (1974) (135)
The inhibition of thrombin-dependent positive-feedback reactions is critical to the expression of the anticoagulant effect of heparin. (1987) (135)
New anticoagulant drugs. (2001) (133)
Thrombosis in antithrombin-III-deficient persons. Report of a large kindred and literature review. (1992) (133)
Net Clinical Benefit of Adding Clopidogrel to Aspirin Therapy in Patients With Atrial Fibrillation for Whom Vitamin K Antagonists Are Unsuitable (2011) (133)
A comparison of compression ultrasound with color Doppler ultrasound for the diagnosis of symptomless postoperative deep vein thrombosis. (1997) (133)
Heparin-induced skin lesions and other unusual sequelae of the heparin-induced thrombocytopenia syndrome: a nested cohort study. (2005) (132)
The use of D-dimer testing and impedance plethysmographic examination in patients with clinical indications of deep vein thrombosis. (1997) (132)
Elevated platelet-associated IgG in the thrombocytopenia of septicemia. (1979) (131)
Controversies in timing of the first dose of anticoagulant prophylaxis against venous thromboembolism after major orthopedic surgery. (2003) (129)
Aspirin and other platelet-active drugs. The relationship among dose, effectiveness, and side effects. (1989) (129)
Prophylaxis of venous thromboembolism. An overview. (1986) (126)
Impedance plethysmography: the relationship between venous filling and sensitivity and specificity for proximal vein thrombosis. (1978) (126)
Heparin Effect on Bone Density (1990) (125)
Hemorrhagic complications of thrombolytic therapy in the treatment of myocardial infarction and venous thromboembolism. (1989) (123)
Discordance between the anti-Xa activity and the antithrombotic activity in an ultra-low molecular weight heparin fraction. (1982) (121)
The Effects of Standard and Low Molecular Weight Heparin on Bone Nodule Formation In Vitro (1998) (120)
The Relationship of Antiphospholipid Antibodies to Thromboembolic Disease in Systemic Lupus Erythematosus: A Cross-Sectional Study (1991) (119)
Tissue plasminogen activator (rt-PA) vs heparin in deep vein thrombosis. Results of a randomized trial. (1990) (119)
Relevance of preoperative and postoperative blood tests to postoperative leg-vein thrombosis. (1973) (118)
Thrombocytopenia in Septicemia: ? The Role of Disseminated Intravascular Coagulation (1980) (117)
Pulmonary embolism in outpatients with pleuritic chest pain. (1988) (115)
Management of patients with hereditary hypercoagulable disorders. (2000) (113)
Aspirin and other platelet-active drugs. The relationship between dose, effectiveness, and side effects. (1992) (112)
Low-molecular-weight heparinoid orgaran is more effective than aspirin in the prevention of venous thromboembolism after surgery for hip fracture. (1996) (111)
Emery's elements of medical genetics (2015) (110)
Reversal of the anti‐platelet effects of aspirin and clopidogrel (2012) (109)
The haemorrhagic and antithrombotic effects of dermatan sulphate (1986) (108)
A comparison of the thrombolytic and hemorrhagic effects of tissue-type plasminogen activator and streptokinase in rabbits. (1985) (108)
Association between asymptomatic deep vein thrombosis detected by venography and symptomatic venous thromboembolism in patients undergoing elective hip or knee surgery (2007) (107)
Neutralization of Enoxaparine-lnduced Bleeding by Protamine Sulfate (1990) (106)
Comparison of the Non-Specific Binding of Unfractionated Heparin and Low Molecular Weight Heparin (Enoxaparin) to Plasma Proteins (1993) (106)
Safety of Withholding Heparin in Pregnant Women With a History of Venous Thromboembolism (2001) (105)
Relationship of Activated Partial Thromboplastin Time to Coronary Events and Bleeding in Patients With Acute Coronary Syndromes Who Receive Heparin (2003) (105)
American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. (2003) (105)
Hemostatic function, survival, and membrane glycoprotein changes in young versus old rabbit platelets. (1981) (104)
Laboratory Monitoring of Non–Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation: A Review (2017) (104)
Shortening of the bleeding time in rabbits by hydrocortisone caused by inhibition of prostacyclin generation by the vessel wall. (1979) (103)
Heparin induced bleeding. (1984) (102)
An Evaluation of Impedance Plethysmography and 125I-Fibrinogen Leg Scanning in Patients following Hip Surgery (1989) (102)
Heparan sulfate and dermatan sulfate inhibit the generation of thrombin activity in plasma by complementary pathways. (1984) (101)
Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. (2006) (101)
A novel whole blood capillary technic for measuring the prothrombin time. (1987) (101)
Current anticoagulant therapy--unmet clinical needs. (2003) (100)
Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future (2008) (99)
Intermittent compression units for severe post-phlebitic syndrome: a randomized crossover study. (1999) (97)
Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: results from the GUSTO-IIb Trial. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO-IIb) Investigators. (1998) (97)
Unfractionated heparin inhibits thrombin-catalysed amplification reactions of coagulation more efficiently than those catalysed by factor Xa. (1989) (97)
The relation between the activated partial thromboplastin time response and recurrence in patients with venous thrombosis treated with continuous intravenous heparin. (1996) (95)
"Therapeutic range" for oral anticoagulant therapy. (1986) (94)
Recurrent venous thrombosis and heparin therapy: an evaluation of the importance of early activated partial thromboplastin times. (1999) (93)
Clinical features and diagnosis of venous thrombosis. (1986) (93)
The relative importance of thrombin inhibition and factor Xa inhibition to the antithrombotic effects of heparin (1985) (93)
Clinical experts or methodologists to write clinical guidelines? (2009) (92)
Cost-effectiveness of primary and secondary prevention of fatal pulmonary embolism in high-risk surgical patients. (1982) (91)
Platelet-inhibiting drugs in the prevention of clinical thrombotic disease (first of three parts). (1975) (89)
Plasma fibrinopeptide A levels in symptomatic venous thromboembolism. (1978) (88)
Unexpected vitamin K deficiency in hospitalized patients. (1973) (87)
Streptokinase Therapy in Acute Major Pulmonary Embolism: Effectiveness and Problems (1968) (87)
Reduction of out-of-hospital symptomatic venous thromboembolism by extended thromboprophylaxis with low-molecular-weight heparin following elective hip arthroplasty: a systematic review. (2003) (85)
Low-molecular-weight heparin : A review of the results of recent studies of the treatment of venous thromboembolism and unstable angina. (1998) (85)
Ardeparin (low-molecular-weight heparin) vs graduated compression stockings for the prevention of venous thromboembolism. A randomized trial in patients undergoing knee surgery. (1996) (85)
Limitations of Impedance Plethysmography in the Diagnosis of Clinically Suspected Deep-Vein Thrombosis (1993) (85)
Comparison of the Accuracy of Impedance Plethysmography and Compression Ultrasonography in Outpatients with Clinically Suspected Deep Vein Thrombosis (1995) (84)
Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range. (1992) (84)
Fibrinolytic Variables in Patients with Recurrent Venous Thrombosis: a Prospective Cohort Study (2001) (84)
Effects of long-term, moderate-intensity oral anticoagulation in addition to aspirin in unstable angina (2001) (83)
Prevention of venous thrombosis by intermittent sequential calf compression in patients with intracranial disease. (1979) (82)
Clinical Experience with Anticoagulant Therapy During Pregnancy (1970) (81)
The optimal duration of anticoagulant therapy for venous thrombosis. (1995) (81)
Combined antiplatelet and anticoagulant therapy: clinical benefits and risks (2007) (80)
125I-Fibrinogen Leg Scanning: Reassessment of Its Role for the Diagnosis of Venous Thrombosis in Post-Operative Patients (1993) (79)
Accelerated Infusion of Streptokinase for the Treatment of Left-Sided Prosthetic Valve Thrombosis: A Randomized Controlled Trial (2009) (79)
Aspirin inhibits platelet function independent of the acetylation of cyclo-oxygenase. (1982) (78)
Prevention of venous thromboembolism. (2008) (77)
Endothelial Cells Produce a Lipoxygenase Derived Chemo-Repellent which Influences Platelet/Endothelial Cell Interactions – Effect of Aspirin and Salicylate (1985) (76)
Acetylsalicylic acid : new uses for an old drug (1982) (76)
A histomorphometric evaluation of heparin-induced bone loss after discontinuation of heparin treatment in rats. (1999) (75)
Sex differences in the antithrombotic effects of aspirin. (1978) (75)
Sustained thrombolysis with DNA-recombinant tissue type plasminogen activator in rabbits. (1985) (74)
Heparin Binding Proteins Contribution to Heparin Rebound After Cardiopulmonary Bypass (1993) (73)
Evaluation of a venous-return assist device to treat severe post-thrombotic syndrome (VENOPTS) (2008) (73)
Effect of nonspecific binding to plasma proteins on the antithrombin activities of unfractionated heparin, low-molecular-weight heparin, and dermatan sulfate. (1997) (73)
Drug-induced thrombocytopenia is associated with increased binding of IgG to platelets both in vivo and in vitro. (1981) (73)
A critical review of the relationship between impaired fibrinolysis and myocardial infarction. (1991) (73)
Real‐world variability in dabigatran levels in patients with atrial fibrillation (2015) (72)
Observations in anticoagulant and thrombolytic therapy in pulmonary embolism. (1975) (72)
Dabigatran attenuates thrombin generation to a lesser extent than warfarin: could this explain their differential effects on intracranial hemorrhage and myocardial infarction? (2013) (72)
Use of a fixed activated partial thromboplastin time ratio to establish a therapeutic range for unfractionated heparin. (2001) (72)
Relationship between the antithrombotic and anticoagulant effects of low molecular weight heparin. (1981) (72)
Epidemiology and pathogenesis of venous thrombosis. (1986) (72)
The Role of Sulfinpyrazone in the Prevention of Arterio‐venous Shunt Thrombosis (1975) (72)
Bleeding and management of bleeding (2006) (71)
Australian multicentre trial of streptokinase in acute myocardial infarction. (1973) (71)
The importance of thrombin inhibition for the expression of the anticoagulant activities of heparin, dermatan sulphate, low molecular weight heparin and pentosan polysulphate (1985) (70)
Deep Vein Thrombosis: New Non-Invasive Diagnostic Tests (1991) (70)
Low Molecular Weight Heparins (LMWH) in the Treatment of Patients with Acute Venous Thromboembolism (1995) (70)
New antithrombotic agents (1999) (70)
Is the dose of warfarin prescribed by American physicians unnecessarily high? (1987) (70)
Suboptimal Monitoring and Dosing of Unfractionated Heparin in Comparative Studies with Low-Molecular-Weight Heparin (2003) (69)
Thrombocytopenia found uncommonly during heparin therapy. (1979) (68)
In vitro comparison of the effect of heparin, enoxaparin and fondaparinux on tests of coagulation. (2002) (68)
Anticoagulants in pregnancy: a review of indications and complications. (1972) (67)
Starting prophylaxis for venous thromboembolism postoperatively. (1995) (67)
Increased platelet adhesiveness in recurrent venous thrombosis and pulmonary embolism. (1965) (66)
The Effect of Thrombin Inhibitors on Tissue Plasminogen Activator Induced Thrombolysis in a Rat Model (1992) (66)
Newly Diagnosed Malignancy in Patients with VenousThromboembolism. Search or Wait and See? (1997) (66)
Clinical Trials That Have Influenced the Treatment of Venous Thromboembolism: A Historical Perspective (2001) (65)
Utility of impedance plethysmography in the diagnosis of recurrent deep-vein thrombosis. (1988) (65)
Sustained antithrombotic activity of hirudin after its plasma clearance: comparison with heparin. (1992) (65)
The value of plasma calibrants in correcting coagulometer effects on international normalized ratios. An international multicenter study. (1995) (65)
The Occurrence of Subsequent Malignancy in Patients Presenting with Deep Vein Thrombosis: Results from a Historical Cohort Study (1998) (65)
HEPARIN IN THE TREATMENT OF VENOUS THROMBOEMBOLIC DISEASE: ADMINISTRATION, CONTROL AND RESULTS (1968) (64)
The direct assay for platelet-associated IgG (PAIgG): lack of association between antibody level and platelet size. (1979) (64)
Electrical Foot Stimulation and Implications for the Prevention of Venous Thromboembolic Disease (2002) (64)
The thrombolytic and hemorrhagic effects of tissue type plasminogen activator: influence of dosage regimens in rabbits. (1985) (63)
Placental Barrier to Coagulation Factors: Its Relevance to the Coagulation Defect at Birth and to Haemorrhage in the Newborn (1969) (63)
Organ-specific bleeding patterns of anticoagulant therapy: lessons from clinical trials (2014) (63)
Effects of heparin, its low molecular weight fractions and other glycosaminoglycans on thrombus growth in vivo. (1985) (62)
Low molecular weight heparin (2014) (62)
Venous thromboembolism. Scope of the problem. (1986) (62)
Von Willebrand's syndrome presenting as an acquired bleeding disorder in association with a monoclonal gammopathy. (1973) (62)
Endotoxin-induced vascular endothelial injury and repair. II. Focal injury, en face morphology, (3H)thymidine uptake and circulating endothelial cells in the dog. (1976) (61)
Use of antithrombotic agents during pregnancy. (1995) (60)
Neonatal coagulation defect due to anticonvulsant drug treatment in pregnancy. (1970) (58)
An Antithrombin III Assay Based on Factor Xa Inhibition Provides a More Reliable Test to Identify Congenital Antithrombin III Deficiency Than an Assay Based on Thrombin Inhibition (1993) (58)
Use of antithrombotic agents during pregnancy. (1993) (57)
Comparison of the in vivo hemorrhagic and antithrombotic effects of a low antithrombin-III affinity heparin fraction. (1982) (57)
Catalysis of Thrombin Inhibition Provides an Index for Estimating the Antithrombotic Potential of Glycosaminoglycans in Rabbits (1987) (57)
Comparison of the effects of apixaban and rivaroxaban on prothrombin and activated partial thromboplastin times using various reagents (2014) (57)
Differences in inhibition of PGI2 production by aspirin in rabbit artery and vein segments. (1980) (57)
The effect of blood storage duration on in‐hospital mortality: a randomized controlled pilot feasibility trial (2012) (57)
Heparin clearance and ex vivo recovery in newborn piglets and adult pigs. (1988) (56)
Guide to Anticoagulant Therapy: Heparin (2001) (56)
Spontaneous bruising associated with a defect in the interaction of platelets with connective tissue. (1967) (56)
Can extra protamine eliminate heparin rebound following cardiopulmonary bypass surgery? (2004) (56)
Hemorrhagic complications of long-term anticoagulant therapy for ischemic cerebral vascular disease. (1986) (55)
Translational Success Stories: Development of Direct Thrombin Inhibitors (2012) (54)
The diagnosis of clinically suspected venous thrombosis. (1984) (54)
The diagnosis and treatment of thrombosis in the cancer patient. (1990) (54)
Mechanism of action and monitoring of anticoagulants. (1986) (54)
Risk of thrombosis with lenalidomide and its prevention with aspirin. (2007) (54)
Practice Guidelines (8th Edition) Chest Physicians Evidence-Based Clinical Vitamin K Antagonists: American College of Pharmacology and Management of the (2008) (54)
American College of Chest Physicians and the National Heart, Lung, and Blood Institute National Conference on Antithrombotic Therapy (1986) (54)
Effects of Dermatan Sulfate and Heparin on Inhibition of Thrombus Growth in Vivo (1989) (54)
Confusion Over the Therapeutic Range for Monitoring Oral Anticoagulant Therapy in North America (1988) (53)
Reevaluation of the sensitivity of impedance plethysmography for the detection of proximal deep vein thrombosis. (1994) (53)
The optimal intensity of oral anticoagulant therapy. (1987) (53)
Heparin as an adjunctive treatment after thrombolytic therapy for acute myocardial infarction. (1991) (53)
Measurement of the activated partial thromboplastin time from a capillary (fingerstick) sample of whole blood. A new method for monitoring heparin therapy. (1991) (52)
The relative importance of thrombin inhibition and factor Xa inhibition to the antithrombotic effects of heparin. (1985) (52)
Ventilation-Perfusion Lung Scanning and the Diagnosis of Pulmonary Embolism: Improvement of Observer Agreement by the Use of a Lung Segment Reference Chart (1992) (52)
New oral anticoagulants for stroke prevention in atrial fibrillation: impact of study design, double counting and unexpected findings on interpretation of study results and conclusions (2014) (52)
Fetal effects of coumadin administered during pregnancy. (1970) (51)
Evidence for a saturable mechanism of disappearance of standard heparin in rabbits. (1987) (51)
The sex-related differences in aspirin pharmacokinetics in rabbits and man and its relationship to antiplatelet effects. (1983) (51)
Reliability of the international normalized ratio for monitoring the induction phase of warfarin: comparison with the prothrombin time ratio. (1996) (50)
Low-molecular-weight heparin for the treatment of venous thromboembolism. (1998) (50)
Anticoagulants during pregnancy. (1989) (50)
Effects of long-term, moderate-intensity oral anticoagulation in addition to aspirin in unstable angina. The Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators. (2001) (50)
Comparison of the anticoagulant intensities of fondaparinux and enoxaparin in the organization to assess strategies in acute ischemic syndromes (OASIS)‐5 trial (2010) (50)
Heparin and related polysaccharides. Structure and activities. (1989) (50)
Sex-related differences in platelet aggregation: influence of the hematocrit (1980) (50)
Energy metabolism in human platelets: interrelationship between glycolysis and oxidative metabolism. (1970) (49)
EFFECT OF FIBRIN AND FIBRINOGEN PROTEOLYSIS PRODUCTS ON CLOT PHYSICAL PROPERTIES. (1965) (49)
Evidence that postoperative fibrinolytic shutdown is mediated by plasma factors that stimulate endothelial cell type I plasminogen activator inhibitor biosynthesis. (1992) (48)
Duration of anticoagulant therapy after first episode of venous thrombosis in patients with inherited thrombophilia. (1997) (48)
AHA Scientific Statement: Guide to anticoagulant therapy: heparin: a statement for healthcare professionals from the American Heart Association. (2001) (48)
Induction of the Acute-Phase Reaction Increases Heparin-Binding Proteins in Plasma (1997) (48)
Thrombosis in antithrombin‐III‐deficient persons. Report of a large kindred and literature review (1993) (48)
Coagulation Studies in Patients with Acute Infectious Hepatitis (1972) (47)
The prolonged effect of sulfinpyrazone on collagen-induced platelet aggregation in vivo. (1978) (47)
Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range. (1995) (46)
Diagnostic tests for deep vein thrombosis. Clinical usefulness depends on probability of disease. (1994) (46)
The incidence of symptomatic venous thromboembolism after enoxaparin prophylaxis in lower extremity arthroplasty: a cohort study of 1,984 patients. Canadian Collaborative Group. (1998) (46)
New antithrombotic agents—insights from clinical trials (2010) (45)
The diagnosis of clinically suspected pulmonary embolism. Practical approaches. (1986) (44)
Prolonged antithrombin activity of low-molecular-weight heparins. Clinical implications for the treatment of thromboembolic diseases. (1995) (44)
Substandard monitoring of warfarin in North America. Time for change. (1992) (44)
Blood tests for the diagnosis of venous and arterial thrombosis (1981) (44)
Evaluation of a standard dosage schedule with streptokinase. (1970) (43)
Treatment of Venous Thromboembolism (1995) (43)
Idiopathic deep venous thrombosis. Is a search for malignant disease justified? (1994) (43)
The diagnosis of pulmonary embolism. (1995) (43)
Role of lipoxygenase metabolism in platelet function: effect of aspirin and salicylate. (1986) (43)
Thrombotic thrombocytopenic purpura: a syndrome of intravascular platelet consumption. (1976) (42)
Very low-dose warfarin prophylaxis to prevent thromboembolism in women with metastatic breast cancer receiving chemotherapy: an economic evaluation. (1995) (42)
The variable anticoagulant response to unfractionated heparin in vivo reflects binding to plasma proteins rather than clearance. (1997) (41)
Advances in Antithrombotic Therapy: Novel Agents (1995) (41)
Rationale behind the development of low molecular weight heparin derivatives. (1985) (41)
Diagnosis of venous thromboembolism. (2008) (40)
Graduated compression stockings for the prevention of post operative venous thromboembolism. (2008) (40)
Alpha 2-antiplasmin supplementation inhibits tissue plasminogen activator-induced fibrinogenolysis and bleeding with little effect on thrombolysis. (1993) (40)
Does acetyl salicylic acid (ASA) have a role in the prevention of venous thromboembolism? (2009) (40)
Venous thromboembolism after long flights: are airlines to blame? (2001) (40)
New antithrombotic agents. (1998) (40)
Peripheral Oxygen Saturation in Older Persons Wearing Nonmedical Face Masks in Community Settings. (2020) (40)
Prevention of venous thrombosis in patients undergoing major orthopaedic surgical procedures. (1989) (40)
Induction of the acute-phase reaction increases heparin-binding proteins in plasma. (1994) (39)
The Basement Membrane Underlying the Vascular Endothelium Is Not Thrombogenic: In Vivo and In Vitro Studies with Rabbit and Human Tissue (1987) (39)
A Randomized Controlled Trial of Low-Molecular-Weight Heparin (Enoxaparin) to Prevent Deep-Vein Thrombosis in Patients Undergoing Elective Hip Surgery (1987) (39)
The Relationships Among Dose, Effectiveness, and Side Effects (1998) (38)
Inhibition of the amplification reactions of blood coagulation by site-specific inhibitors of alpha-thrombin. (1992) (38)
Betrixaban (PRT054021): pharmacology, dose selection and clinical studies. (2014) (38)
Comparison of the effects of streptokinase and heparin on the early rate of resolution of major pulmonary embolism. (1971) (38)
Reflecting on eight editions of the American College of Chest Physicians antithrombotic guidelines. (2008) (38)
Progress review: the relationship between dose of aspirin, side-effects and antithrombotic effectiveness. (1985) (38)
The disappearance of a low molecular weight heparin fraction (CY 216) differs from standard heparin in rabbits. (1987) (38)
Parenteral Anticoagulants (2008) (38)
Multicentric Evaluation of a New PT Reagent Based on Recombinant Human Tissue Factor and Synthetic Phospholipids (1994) (38)
The inhibition by heparin of the intrinsic pathway activation of factor X in the absence of antithrombin-III. (1980) (37)
Platelet Glycolytic Enzymes: Effect of Cellular Disruption Procedures on Activity (1970) (37)
Diagnosis of pulmonary embolism. (1995) (37)
The treatment of venous thromboembolism. (1986) (37)
The reversible binding of vinblastine to platelets: implications for therapy. (1981) (36)
Low molecular weight heparin: laboratory properties and clinical evaluation. A review. (1994) (36)
Vasoflux, a new anticoagulant with a novel mechanism of action. (1999) (36)
Treatment of venous thromboembolic disease. (1976) (36)
Relationship between vessel wall 13-HODE synthesis and vessel wall thrombogenicity following injury: influence of salicylate and dipyridamole treatment. (1990) (35)
Resolution of acute massive pulmonary embolism after pulmonary arterial infusion of streptokinase. (1967) (35)
The inhibition of the anticoagulant activity of heparin by platelets, brain phospholipids, and tissue factor (1984) (35)
Diagnosis of venous thrombosis and pulmonary embolism. (1990) (34)
Introduction: Antithrombotic Therapy—The Evolving Consensus (1998) (34)
Major pulmonary embolism, a correlation of clinical findings, haemodynamics, pulmonary angiography, and pathological physiology. (1972) (34)
Antithrombotic Properties of Heparin in a Neonatal Piglet Model of Thrombin-Induced Thrombosis (1988) (34)
The binding of unfractionated heparin and low molecular weight heparin to thrombin-activated human endothelial cells. (1999) (33)
A systematic review of contemporary trials of anticoagulants in orthopaedic thromboprophylaxis: suggestions for a radical reappraisal (2015) (33)
Prognosis in acute pulmonary embolism (1999) (33)
Optimal intensity and monitoring warfarin. (1995) (33)
The value of adding impedance plethysmography to 125I-fibrinogen leg scanning for the detection of deep vein thrombosis in high risk surgical patients: a comparative study between patients undergoing general surgery and hip surgery. (1979) (33)
Venous thromboembolism : natural history, diagnosis, and management (1987) (33)
CCS Consensus Conference 2003: Assessment of the cardiac patient for fitness to drive and fly - Executive summary (2004) (32)
Placental transport of low molecular weight heparin in the pregnant sheep (1985) (32)
A novel antithrombin-heparin covalent complex: antithrombotic and bleeding studies in rabbits. (1998) (32)
A comparison of the effects of aspirin and dipyridamole on platelet aggregation in vivo and ex vivo. (1978) (31)
Type 1 plasminogen activator inhibitor is not an acute phase reactant in rats. Lack of IL-6- and hepatocyte-dependent synthesis. (1993) (31)
The thrombogenicity of prothrombin complex concentrates: I. The relationship between in vitro characteristics and in vivo thrombogenicity in rabbits. (1980) (31)
Randomized controlled trial of a new portable calf compression device (Venowave) for prevention of venous thrombosis in high‐risk neurosurgical patients (2012) (30)
The Effect of Collagen on Platelet Glycolysis and Nucleotide Metabolism (1968) (30)
Electrical Foot Stimulation: A Potential New Method of Deep Venous Thrombosis Prophylaxis (2010) (30)
Uncontrolled PGI2 production by whole vessel wall segments due to thrombin generation in vivo and its prevention by heparin. (1979) (30)
Utility of ultrasound imaging of the lower extremities in the diagnostic approach in patients with suspected pulmonary embolism (2001) (30)
A guide to GRADE guidelines for the readers of JTH (2013) (30)
Hemorrhagic complications of thrombolytic therapy in the treatment of myocardial infarction and venous thromboembolism. (1995) (29)
Sex-related differences in platelet aggregation: influence of the hematocrit. (1980) (29)
Antithrombotic and bleeding effects of glycosaminoglycans with different degrees of sulphation (1989) (29)
Familial Thrombophilia: A Review Analysis (1996) (29)
Detection of previous proximal venous thrombosis with Doppler ultrasonography and photoplethysmography. (1989) (28)
Bleeding in patients with atrial fibrillation treated with dabigatran, rivaroxaban or warfarin: A retrospective population-based cohort study. (2016) (28)
Use of anticoagulants during pregnancy. (1989) (28)
Mechanisms for Inhibition of the Generation of Thrombin Activity by Sulfated Polysaccharides a (1986) (28)
Advances and controversies in the diagnosis, prevention, and treatment of venous thromboembolism. (1981) (28)
Reversal of the anticoagulant effects of warfarin by vitamin K1. (1998) (28)
From unfractionated heparins to low molecular weight heparins. (1990) (28)
Apixaban-Calibrated Anti-FXa Activity in Relation to Outcome Events and Clinical Characteristics in Patients with Atrial Fibrillation: Results from the AVERROES Trial (2017) (28)
Role of phenotypic and genetic testing in managing clopidogrel therapy. (2014) (28)
Resolution of experimental pulmonary emboli with heparin and streptokinase in different dosage regimens. (1974) (28)
New anticoagulants. (2005) (28)
Endotoxin-induced endothelial injury and repair. I. Endothelial cell turnover in the aorta of the rabbit. (1975) (27)
Aspirin: Its Effect on Platelet Glycolysis and Release of Adenosine Diphosphate (1969) (27)
Effect of Aspirin and Saiicylate on Platelet‐Vessel Wall Interactions in Rabbits (1984) (27)
Perioperative management of patients receiving oral anticoagulants. (2003) (27)
Relation between bleeding time and platelet connective tissue reaction after aspirin. (1973) (26)
Reactivation of ischemic events in acute coronary syndromes: results from GUSTO-IIb. Gobal Use of Strategies To Open occluded arteries in acute coronary syndromes. (2001) (26)
Hypofibrinogenaemia without increased fibrinolysis in leukaemia. (1967) (26)
Multiple daily doses of acetyl‐salicylic acid (ASA) overcome reduced platelet response to once‐daily ASA after coronary artery bypass graft surgery: a pilot randomized controlled trial (2015) (26)
Outcome of abnormal impedance plethysmography results in patients with proximal-vein thrombosis: frequency of return to normal. (1984) (26)
Hypersulfated Low Molecular Weight Heparin with Reduced Affinity for Antithrombin Acts as an Anticoagulant by Inhibiting Intrinsic Tenase and Prothrombinase* (2001) (26)
Lack of consistency in the relationship between asymptomatic DVT detected by venography and symptomatic VTE in thromboprophylaxis trials (2015) (25)
Antithrombotic therapy in deep vein thrombosis and pulmonary embolism. (1992) (25)
Intermittent compression units for the postphlebitic syndrome. A pilot study. (1989) (25)
Clinical use of low molecular weight heparins and heparinoids. (1988) (25)
Use of antithrombotic agents during pregnancy. (1998) (25)
A cost-effectiveness analysis of alternative approaches for long-term treatment of proximal venous thrombosis. (1984) (25)
Platelet-inhibiting drugs in the prevention of clinical thrombotic disease (third of three parts). (1975) (25)
Effects of sodium warfarin administered during pregnancy in mice. (1974) (25)
Sex related differences in platelet function: the effect of aspirin. (1982) (25)
A comparison of lyophilized artificially depleted plasmas and lyophilized plasmas from patients receiving warfarin in correcting for coagulometer effects on international normalized ratios. (1995) (24)
Heparin with low affinity to antithrombin III inhibits the activation of prothrombin in normal plasma. (1982) (24)
Edoxaban for the Treatment of Venous Thromboembolism in Patients with Cancer. (2018) (23)
Effect of streptokinase on hemostasis. (1968) (23)
The use of an indwelling Teflon catheter for subcutaneous heparin administration during pregnancy. A randomized crossover study. (1993) (22)
Comparative value of tests for the diagnosis of venous thrombosis (1978) (22)
Hirudin causes more bleeding than heparin in a rabbit ear bleeding model. (1998) (22)
Reply: Warfarin: Less May Be Better (1997) (22)
Can extra protamine eliminate heparin rebound following cardiopulmonary bypass surgery (2004) (22)
Placental barrier to coagulation factors: its relevance to the coagulation defect at birth and to haemorrhage in the newborn. (1969) (22)
A Low Molecular Weight Heparin Alters the Fetal Coagulation System in the Pregnant Sheep (1986) (22)
The diagnostic value of the fibrinogen/fibrin fragment E antigen assay in clinically suspected deep vein thrombosis. (1982) (22)
Effects on Thrombin Generation of Single Injections of Hirulog™ in Patients with Calf Vein Thrombosis (1994) (22)
Use of bedside activated partial thromboplastin time monitor to adjust heparin dosing after thrombolysis for acute myocardial infarction: results of GUSTO-I. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. (1998) (21)
Rationale for development of low-molecular-weight heparins and their clinical potential in the prevention of postoperative venous thrombosis. (1991) (21)
Overview of low molecular weight heparins and heparinoids: basic and clinical aspects. (1992) (21)
New anticoagulants. (2001) (21)
Evidence for the needs of out-of-hospital thrombosis prophylaxis: introduction. (1998) (21)
Reduction in Mortality following Elective Major Hip and Knee Surgery: A Systematic Review and Meta-Analysis (2019) (21)
Increased Heparin Clearance in Experimental Pulmonary Embolism (1977) (21)
Special report: a simple system for the derivation of International Normalized Ratios for the reporting of prothrombin time results with North American thromboplastin reagents. (1989) (21)
Platelet Adhesiveness: A Comparison of the Rotating Bulb and Glass-Bead Column Methods (1966) (21)
Radioimmunoassay of Fibrinogen and Its Proteolysis Products (1968) (21)
Activation of factor X and prothrombin in antithrombin-III depleted plasma: the effects of heparin. (1981) (21)
New oral anticoagulants: not quite there yet. (2009) (20)
Oral anticoagulant therapy. Urgent need for standardization. (1992) (20)
The emerging role of low-molecular-weight heparin in cardiovascular medicine. (2000) (20)
Platelet suppressive therapy. (1978) (20)
Platelet function in health and disease. (1971) (20)
Latex-bound antifibrinogen test for plasma fibrinogen assay (1968) (20)
Optimal therapeutic range for oral anticoagulants [published erratum appears in Chest 1989 Oct;96(4):962] (1989) (20)
Mechanisms for elevated fibrin/fibrinogen degradation products in acute experimental pulmonary embolism (1975) (19)
Management of anti-thrombin III deficiency during pregnancy without administration of anti-thrombin III. (1986) (19)
Comparison of the haemorrhagic effects of porcine and bovine heparin in rabbits. (1979) (19)
Apixaban for Stroke Prevention in Atrial Fibrillation: Why are Event Rates Higher in Clinical Practice than in Randomized Trials?—A Systematic Review (2020) (19)
Influence of low-intensity warfarin treatment on patients' perceptions of quality of life. (1991) (19)
Shortening of the bleeding time in thrombocytopenic rabbits after exposure of jugular vein to high aspirin concentration. (1979) (19)
Rationale and results of thrombolytic therapy for deep-vein thrombosis (1992) (19)
EVALUATION OF SUBCUTANEOUS CALCIUM HEPARIN THERAPY IN THE TREATMENT OF THROMBO‐EMBOLIC DISEASE (1970) (18)
Circulating immune complexes in thrombotic thrombocytopenic purpura (TTP) (1978) (18)
Energy Metabolism in Washed Human Platelets Responsive to ADP: Comparison with Platelets in Plasma (1973) (18)
125-I-labeled fibrinogen scanning. Use in the diagnosis of venous thrombosis. (1975) (18)
Preparation and partial characterization of human plasma depleted of antithrombin-III by heparin-sepharose affinity chromatography. (1980) (18)
Advances in antithrombotic drug therapy for coronary artery disease. (1995) (18)
Platelet-inhibiting drugs iee parts). (1975) (18)
Platelet Age: its Relationship to Platelet Size, Function and Metabolism (1972) (18)
Clinical experience with anticoagulant therapy during pregnancy. (1970) (17)
Effect of aspirin on hemostasis and thrombosis. (1981) (17)
A new short infusion dosage regimen of recombinant tissue plasminogen activator in patients with venous thromboembolic disease. (1990) (17)
Long-term anticoagulant therapy in patients with venous thrombosis. (1983) (17)
Induction of aggregation of human blood platelets by ultraviolet light: action spectrum and structural changes. (1973) (17)
Treatment of pulmonary embolism. (1987) (17)
Recurrent leg symptoms following deep vein thrombosis. A diagnostic challenge. (1985) (17)
The development and application of a serum assay for platelet-bindable IgG (S-PBIgG). (1981) (17)
ORAL ANTICOAGULANT DRUGS. AUTHOR'S REPLIES (1992) (17)
Immunodepletion of human plasma factor VIII. (1980) (17)
Guidelines for Antithrombotic Therapy (2004) (17)
[Expert consensus document on the use of antiplatelet agents]. (2004) (16)
Prevention of deep venous thrombosis. (1981) (16)
An evaluation of suloctidil in the prevention of deep vein thrombosis in neurosurgical patients. (1985) (16)
The Current Status of Platelet Suppressive Drugs in the Treatment of Thrombosis (1975) (16)
Comparison of the relative efficacy and safety of low molecular weight heparin and unfractionated heparin for the treatment of venous thrombosis. (1996) (16)
Thrombosis and anticoagulation. (1999) (16)
Canadian Consensus Conference on Coronary Thrombolysis--1994 update. (1994) (16)
Sex-related differences in the efficacy of acetylsalicylic acid (ASA) : the absorption of ASA and its effect on collagen-induced thromboxane B2 generation. (1981) (16)
Simplification of the sequential impedance plethysmograph technique without loss of accuracy. (1980) (16)
Direct thrombin inhibitors in cardiovascular disease (2012) (15)
Inhibition of arterial thrombosis and platelet function by nafazatrom. (1982) (15)
Guidelines for anticoagulant use in acute coronary syndromes (2008) (15)
Effect of probe design on accuracy and reliability of pulse oximetry in pediatric patients. (1999) (15)
Investigation of the Mechanism of False Positive 125I‐Labelled Fibrinogen Scans (1974) (15)
The development and validation of an instrument to measure the quality of health research reports in the lay media (2017) (15)
Prophylaxis of venous thromboembolism (1984) (15)
Treatment of venous thromboembolism. (1986) (15)
Diagnosis and treatment of venous thromboembolism. (2002) (15)
Relation between clopidogrel active metabolite levels and different platelet aggregation methods in patients receiving clopidogrel and aspirin (2012) (15)
Heparin resistance in acute coronary syndromes (2007) (15)
Dose antiplatelet agents; the relationship among side effects, and antithrombotic effectiveness. (1986) (14)
Factors Influencing the Reported Sensitivity and Specificity of Impedance Plethysmography for Proximal Deep Vein Thrombosis (1994) (14)
Standard and Low Molecular Weight Heparin Have no Effect on Tissue Plasminogen Activator Induced Plasma Clot Lysis or Fibrinogenolysis (1991) (14)
Low Molecular Weight Heparin for the Out-of-Hospital Treatment of Venous Thrombosis: Rationale and Clinical Results (1997) (14)
Prevention of venous thromboembolism after surgery: A review of enoxaparin (1992) (14)
Saddle pulmonary embolism: a surgical emergency? (1970) (14)
Contribution of Red Blood Cells to the Saturable Mechanism of Heparin Clearance (1990) (14)
Effectiveness of anticoagulants. (1986) (14)
Fifty years of research on antithrombotic therapy: Achievements and disappointments. (2019) (14)
In vivo effects of low molecular weight heparins on experimental thrombosis and bleeding. (1986) (14)
Once versus twice daily aspirin after coronary bypass surgery: a randomized trial (2017) (14)
Modulating the coagulation cascade: New targets for antithrombotics and anticoagulantsIntroduction☆☆☆ (2001) (14)
Low molecular weight heparins (1994) (14)
ISOPROTERENOL IN MASSIVE PULMONARY EMBOLISM: HAEMODYNAMIC AND CLINICAL EFFECTS (1968) (13)
International Committee Communications (1979) (13)
Mechanistic Basis for the Differential Effects of Rivaroxaban and Apixaban on Global Tests of Coagulation (2018) (13)
Critical evaluation of platelet-inhibiting drugs in thrombotic disease. (1975) (13)
Hemorrhagic complications of long-term anticoagulant therapy. (1989) (13)
Subtle differences in commercial heparins can have serious consequences for cardiopulmonary bypass patients: A randomized controlled trial. (2012) (13)
Laboratory monitoring of low‐molecular‐weight heparin therapy (2004) (13)
Determination of sulphinpyrazone in patient plasma by gas chromatography. (1978) (13)
The pharmacokinetics and bioavailability of subcutaneously administered dihydroergotamine, heparin and the dihydroergotamine-heparin combination. (1983) (13)
Rationale and Design of the Informing Fresh versus Old Red Cell Management (INFORM) Trial: An International Pragmatic Randomized Trial. (2016) (13)
Evolution of Thrombosis (1987) (13)
Optimal dose for starting and maintaining low-dose aspirin. (1993) (12)
Evidence for the Needs of Out-of-Hospital Thrombosis ProphylaxisThe Incidence of Symptomatic Venous Thromboembolism After Enoxaparin Prophylaxis in Lower Extremity Arthroplasty: A Cohort Study of 1,984 Patients (1998) (12)
Antithrombins: their potential as antithrombotic agents. (1992) (12)
Risk of haemorrhage associated with long term anticoagulant therapy (1985) (12)
Increased dipyridamole plasma concentrations associated with salicylate administration. Relationship to effects on platelet aggregation in vivo. (1979) (12)
Infection with the Human Immunodeficiency Virus: Clinical Manifestations and Their Relationship to Immune (1987) (12)
International Committee Communications. Standardization and clinical use of LMW heparin. Report of the ICTH Heparin Subcommittee, Brussels, July 1987. (1988) (12)
10 Anticoagulant therapy in venous thromboembolism (1990) (12)
ARTERIAL THROMBOSIS IN A PATIENT WITH CHRONIC THROMBOCYTOPENIA SUCCESSFUL TREATMENT WITH INTRAARTERIAL INFUSION OF STREPTOKINASE (1969) (11)
Multicentric evaluation of heparinase on aPTT, thrombin clotting time and a new PT reagent based on recombinant human tissue factor (1996) (11)
(8th Edition) Evidence-Based Clinical Practice Guidelines American College of Chest Physicians Antithrombotic Therapy, and Pregnancy: Venous Thromboembolism, Thrombophilia, (2008) (11)
ANTITHROMBOTIC THERAPY AND PREVENTION OF THROMBOSIS, 9TH ED: ACCP GUIDELINES (2012) (11)
Early rate of resolution of major pulmonary embolism. A study of angiographic and haemodynamic changes occurring in the first 24 to 48 hours. (1971) (11)
Anticoagulation for venous thromboembolism (2007) (11)
Timing the First Postoperative Dose of Anticoagulants: Lessons Learned From Clinical Trials. (2015) (11)
Monitoring the ACTIVE-W trial: some issues in monitoring a noninferiority trial. (2008) (11)
Antithrombin-heparin covalent complex reduces microemboli during cardiopulmonary bypass in a pig model. (2010) (11)
Venous thromboembolism prophylaxis: do trial results enable clinicians and patients to evaluate whether the benefits justify the risk? Proceedings of an Ad Hoc Working Group Meeting (2013) (11)
Pulmonary embolism in the elderly. (1991) (11)
Platelet-phosphohexokinase levels in Down's syndrome. (1968) (10)
Comparison of in Vivo and in Vitro Effects of Platelet Function Suppressing Drugs (1975) (10)
Distribution of Platelet Hexokinase and the Effect of Collagen (1967) (10)
Aspirin response variability after major orthopedic surgery. (2012) (10)
Effects of methyl prednisolone on platelet adhesion to damaged aorta bleeding time and platelet survival (1976) (10)
Prolonged Prothrombin Time and Partial Thromboplastin Time in Disseminated Intravascular Coagulation not Due to Deficiency of Factors V and VIII (1973) (10)
IN VIVO ACTIVITY OF A NEW HEPARINOID (1985) (10)
Relevance of Platelet Function Tests in Assessing the Antithrombotic Effects of Drugs (1975) (10)
Comparison of the relative efficacy and safety of low-molecular-weight heparin and unfractionated heparin for the treatment of venous thrombosis. (1996) (10)
Establishing an optimal therapeutic range for coumarins: filling in the gaps. (2004) (10)
Special Report Guide to Anticoagulant Therapy Part 1: Heparin (2005) (10)
Comparative effects of heparin and LMW heparin on hemostasis. (1991) (9)
Erythrocyte and platelet glucose 6-phosphate dehydrogenase in normal and mutant caucasians. (2009) (9)
The rate of resolution of pulmonary embolism and its effects on early survival. (1970) (9)
AUSTRALIAN MULTICENTRE TRIAL OF STREPTOKINASE IN ACUTE MYOCARDIAL INFARCTION (1977) (9)
Acute major pulmonary embolism as a cause of exaggerated respiratory blood pressure variation and pulsus paradoxus. (1972) (9)
Reliability of non-invasive tests for the diagnosis of venous thrombosis. (1991) (9)
Selection and results of antiplatelet therapy in the prevention of stroke and myocardial infarction. (1981) (9)
Randomized comparison of a novel anticoagulant, vasoflux, and heparin as adjunctive therapy to streptokinase for acute myocardial infarction: results of the VITAL study (Vasoflux International Trial for Acute Myocardial Infarction Lysis). (2001) (9)
Duration of anticoagulant therapy for venous thromboembolism (2009) (9)
New antithrombotics. (1995) (9)
Mandatory contrast-enhanced venography to detect deep-vein thrombosis (DVT) in studies of DVT prophylaxis: upsides and downsides (2013) (9)
Papaverine injection into the hindlimb circulation stimulates ventilation in sheep. (1996) (8)
Optimal dosage regimens of tissue-type plasminogen activator. (1987) (8)
Sample Size in the Planning and Interpretation of Clinical Trials (1987) (8)
Chlorpromazine bioavailability from a topical gel formulation in volunteers. (2013) (8)
Therapeutic range for the control of oral anticoagulant therapy. (1986) (8)
Wells PS, Hirsh J, Anderson DR, et al: Accuracy of clinical assessment of deep-vein thrombosis (1995) (8)
Dabigatran: ready for prime time? (2010) (8)
Venous Thromboembolism: Diagnosis, Treatment, Prevention (1975) (8)
Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). How we diagnose and treat deep vein thrombosis. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. (2004) (8)
WARFARIN : LESS MAY BE BETTER. AUTHORS' REPLY (1997) (8)
The thrombogenicity of prothrombin complex concentrates: II. The effect of thrombocytopenia on in vivo thrombogenicity in rabbits. (1980) (7)
Comparison of the relative efficacy and safety of low molecular weight heparin and unfractionated heparin for the treatment of deep venous thrombosis. (1997) (7)
Definition of High Risk/High Response Population for Stroke in Patients with Transient Ischemic Attacks (1979) (7)
Effects of Penicillin G and Cephalothin on Platelet Function in Vivo (1976) (7)
Effect of activation of the fibrinolytic mechanism on experimental platelet-rich thrombi in rabbits. (1968) (7)
Platelets, Drugs and Thrombosis of Arteriovenous Shunts (1975) (7)
The optimal antithrombotic dose of aspirin. (1985) (7)
Effects of heparin fractions of different affinities to antithrombin III and thrombin on the inactivation of thrombin and factor Xa by antithrombin III. (1984) (7)
In Vitro Reversal of the Anti-Aggregant Effect of Ticagrelor Using Untreated Platelets (2018) (7)
Effect of streptokinase therapy on experimental fibrin-rich arterial thrombi. (1971) (7)
Real‐world variability in dabigatran levels in patients with atrial fibrillation: reply (2015) (6)
Anticoagulant and platelet antiaggregant agents (1986) (6)
Hemostasis & thrombosis: A conceptual approach (1979) (6)
A comparison of the quantitative ristocetin von Willebrand factor assay by using fresh and fixed platelets. (1980) (6)
Thrombotic Thrombocytopenic Purpura: Mechanism for Effectiveness of Plasmapheresis (1979) (6)
Use of warfarin (coumarin). (1993) (6)
New approaches for deep vein thrombosis occurring after surgery. (1984) (6)
Hot clot scan. A method for the accurate identification of experimental pulmonary emboli. (1974) (6)
Streptokinase in the treatment of major pulmonary embolism--experience with twenty-five patients. (1970) (6)
Comparison of platelet scintigraphy, impedance plethysmography gray scale and color flow duplex ultrasound and venography for the diagnosis of venous thrombosis. (1990) (6)
Active metabolite concentration of clopidogrel in patients taking different doses of aspirin: results of the interaction trial (2015) (6)
Plasma Apixaban Levels in Patients Treated Off Label With the Lower Dose. (2020) (6)
The Additive Effect of Low Molecular Weight Heparins on Thrombin Inhibition by Dermatan Sulfate (1993) (6)
How can we reduce disagreement among guidelines for venous thromboembolism prevention? (2010) (6)
The effect of experimental hematoma on serum levels of fibrinogen-related antigen. (1976) (5)
BIOCHEMISTRY AND ANTICOAGULANT EFFECTS OF LOW MOLECULAR WEIGHT HEPARINS AND HEPARIN (1995) (5)
Advances and contemporary issues in prophylaxis for deep vein thrombosis. (2003) (5)
Quantifying immature platelets as markers of increased platelet production after coronary artery bypass grafting surgery (2018) (5)
Antithrombotic therapy. Introduction. (1992) (5)
Urgent Need for Standardization (2005) (5)
Diagnosis of Thrombosis Evaluation of 125I-fibrinogen Scanning and Blood Tests (1974) (5)
Evaluation of a VENOus-Return Assist Device (Venowave™) To Treat Severe Post-Thrombotic Syndrome (VENOPTS): A Randomized Controlled Trial. (2006) (5)
4 Clinical potential of low molecular weight heparins (1990) (5)
Pseudothrombosis in pregnancy. (1988) (5)
Prevention of venous thrombosis in patients undergoing major orthopaedic surgical procedures. (1990) (5)
Antithrombotic agents in coronary artery disease. (1992) (5)
Clinical potential of low molecular weight heparins. (1990) (5)
Relationship between dose, anticoagulant effect and the clinical efficacy and safety of heparin. (1992) (5)
Factors XI and XII are low in subjects with liver disease (1983) (5)
Low-molecular-weight heparin for the out-of-hospital treatment of venous thrombosis: rationale and clinical results. (1997) (5)
(8th Edition) Evidence-Based Clinical Practice Guidelines American College of Chest Physicians Antithrombotic and Thrombolytic Therapy: (2008) (4)
Treatment of Heparin-Induced Thrombocytopenia (2013) (4)
Heparin Therapy in Venous Thromboembolism (1989) (4)
Alterations Of Platelet Morphology In Human Ischemic Heart Disease And In An Acute Thrombosis Rabbit Model (1981) (4)
Anticoagulants in venous thromboembolism. Prophylactic and therapeutic use. (1974) (4)
Antithromboric agents in coronary artery disease (1992) (4)
Increased platelet destruction. (1982) (4)
Fixed-Dose, Weight-Adjusted, Unfractionated Heparin (UFH) Given Subcutaneously (sc) without Laboratory Monitoring for Acute Treatment of Venous Thromboembolism (VTE): Randomized Comparison with Low-Molecular-Weight-Heparin (LMWH). (2004) (4)
Heparin enhances active site-dependent binding of tissue-type plasminogen activator to endothelial cells (1992) (4)
Comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic diseases in patients with and without malignancy (2000) (4)
The activated partial thromboplastin time in the control of heparin treatment. (1970) (4)
Venous thrombosis and pulmonary embolism : diagnostic methods (1987) (4)
A comparison of lyophilized artificially depleted plasmas and lyophilized plasmas from warfarin treated patients in correcting for coagulometer effects on international normalized ratios (1995) (4)
Effects of Thrombolytic Therapy on Hemorrhage from Post-operative Wounds (1974) (4)
Theoretical and Practical Aspects of Thrombolytic Therapy (1977) (4)
Theoretical and Practical Aspects of Thrombolytic Therapy (1977) (4)
Solving the mystery of excessive warfarin-induced bleeding: A personal historical perspective (2014) (4)
ANTIPLATELET AGENTS: THEIR ROLE IN THE PREVENTION OF SUDDEN DEATH (1982) (4)
Prophylaxis and therapy of venous thromboembolism. (1979) (4)
Heparin enhances active site-dependent binding of tissue-type plasminogen activator to endothelial cells. (1992) (4)
Prolonged Inhibition of PGI2 Production and Associatedincreased Thrombogenic Effect in Arteries After Aspirin Administration (1979) (4)
Antithrombotic Drugs: Part I (2012) (3)
Practice Guidelines (8th Edition) Clinical of Chest Physicians Evidence-Based Parenteral Anticoagulants: American College (2008) (3)
Platelet-associated IgG in septicemia. (1979) (3)
Hemorrhagic complications of thrombolytic therapy in the treatment of myocardial infarction and venous thromboembolism. (1992) (3)
The factor VIII-independent activation of factor X by factors IXa and VII in plasma. (1981) (3)
Venous Thromboembolism (2020) (3)
An overview of clinical trials of low molecular weight heparin fractions. (1988) (3)
Inadequate monitoring of warfarin dosage [letter] [see comments] (1992) (3)
Review in translational hematology New anticoagulants (2004) (3)
Aspirin and other platelet active drugs. Relationship among dose, effectiveness, and side effects. (1989) (3)
The in Vivo Evaluation of the Hemostatic Function of Stored Human Platelets (1977) (3)
Mechanisms for elevated fibrin/fibrinogen degradation products in acute experimental pulmonary embolism. (1975) (3)
HEPARIN THERAPY IN VENOUS THROMBOSIS AND PULMONARY EMBOLISM: CLINICAL AND EXPERIMENTAL OBSERVATIONS (1979) (3)
Oral Anticoagulation Treatment in the Elderly (2016) (3)
A Paired Comparison of the Accuracy of Two Impedance Plethysmographs (1997) (3)
Anticoagulant therapy in venous thromboembolism. (1990) (3)
The Lack Of Relationship Between Anti-Xa Activity And Antithrombotic Activity Of Low Molecular Weight Heparin (1981) (3)
Evaluating bleeding complications of thromboprophylaxis after hip replacement: a systematic review (2003) (3)
Deep Vein Thrombosis Prophylaxis: Response (2009) (3)
Evidence-Based Clinical Practice Guidelines American College of Chest Physicians and Prevention of Thrombosis, 9th ed: Antiplatelet Drugs : Antithrombotic Therapy (2012) (3)
Choice of low molecular weight heparins (2003) (3)
Transforming evidence into practice: evidence-based consensus (1993) (3)
RELATIONSHIP BETWEEN VESSEL WALL 13-HODE PRODUCTION AND SUBENDOTHELIAL BASEMENT MEMBRANE THROMBORESISTANCE: INFLUENCE OF SALICYLATE (1987) (3)
Risk of Haemorrhage Associated with Long Term (1985) (3)
The use of electromyography to detect muscle contraction responsible for falsely positive impedance plethysmographic results. (1979) (3)
Divergent effects of aspirin and salicylate on glucose and glycogen metabolism in human platelets (1971) (3)
Practical application of 125I-fibrinogen leg scanning. (1981) (3)
Low-dose aspirin reduced DVT and pulmonary embolism but increased postoperative bleeding requiring transfusion in hip-surgery patients (2001) (2)
Bleeding in Patients with Atrial Fibrillation Treated with Non Vitamin K Antagonist Oral Anticoagulants: A Population-Based Study (2014) (2)
When and how to use heparin prophylaxis and treatment. (1979) (2)
PLATELETS: A PORTSMOUTH SYNDROME ? (1967) (2)
Use of plasminogen activators in venous thrombosis (1990) (2)
Prevention of Venous Thrombosis in Neurosurgical Patients by Intermittent Calf Compression (1975) (2)
Deep vein thrombosis: recovery or recurrence? (1995) (2)
Optimum Use of Anticoagulants in Pregnancy (1988) (2)
Standardization and Clinical Use of LMW Heparin (1988) (2)
Recent clinical trials in the treatment of venous thromboembolism and unstable angina with low molecular weight heparins (1998) (2)
Impact of cost on use of non-vitamin K antagonists in atrial fibrillation patients in Ontario, Canada (2018) (2)
Platelet Survival, Fibrinolytic Activity, Antithrombin III (AT III) Level and Fibrinogen Survival in Venous Thromboembolism (VTE) (1975) (2)
Developing a novel antithrombotic in the academic environment. (2001) (2)
Inadequate monitoring of warfarin dosage. (1992) (2)
Use of antithrombotic agents pregnancy (1992) (2)
Postthrombotic Syndrome After Hip or Knee Arthroplasty (2015) (2)
In vitro effect of hirudin on recalcification time. (1994) (2)
Randomized Trial of Warfarin Nomograms [3] (multiple letters) (2004) (2)
ORGARAN Extending the Frontiers of Venous Thrombosis Prophylaxis (1992) (2)
Randomized trial of warfarin nomograms. (2004) (2)
Methodologists are not qualified to write clinical guidelines – Authors' reply (2009) (2)
ANTICOAGULANTS AFTER OPEN‐HEART SURGERY (1970) (2)
The value of monitoring heparin therapy in the prevention of recurrence in patients with venous thromboembolic disease. (1973) (2)
Antithrombotic Drugs: Part II (2012) (2)
Haemorrhagic Disorders and Fibrinolysis (1973) (2)
Platelet inhibitors in the treatment of thrombosis. (1978) (2)
DEEP VEIN THROMBOSIS PROPHYLAXIS IN SURGICALLY TREATED FRACTURED HIP PATIENTS (1987) (2)
The Diagnosis of Established Deep Vein Thrombosis (1979) (2)
Bleeding in Patients with Atrial Fibrillation Treated with Different Doses of Direct Oral Anticoagulants and Vitamin K Antagonists: A Population-Based Study (2016) (2)
Maximizing the benefits of thrombolytic therapy for acute myocardial infarction. (1995) (2)
ORGARAN Extending the Frontiers of Venous Thrombosis Prophylaxis (1992) (2)
Evaluation of a venous-return assist device (venowave) to treat post-thrombotic syndrome: a phase II study (2003) (2)
Can a Single Measurement of Apixaban Levels Identify Patients at Risk of Overexposure? A Prospective Cohort Study (2021) (2)
Evidence-Based Clinical Practice Guidelines American College of Chest Physicians and Prevention of Thrombosis , 9 th ed : Medical Patients : Antithrombotic Therapy Prevention of Thrombosis in Surgical and Approach to Outcome Measurement in the (2012) (2)
Sex-Related Differences In Aspirin Pharmacokinetics Following IV Injection In Rabbits (1981) (1)
Normalization of Platelet Survival in an Experimental Model after Platelet Exposure of Thrombin in Vitro or adp in Vivo (1977) (1)
Diagnosis of thrombophlebitis. (1986) (1)
INCREASED SULFATION INCREASES THE BLEEDING SIDE-EFFECTS OF GLYCOSAMINOGLYCANS (1987) (1)
PGI2 Production and Effect of Aspirin on Endothelial Cells and Non-Endothelial Cells of the Vessel Wall (1979) (1)
Coronary thrombolysis: hemorrhagic complications. (1993) (1)
Warfarin Therapy American Heart Association/American College of Cardiology Foundation Guide to (2013) (1)
Suboptimal monitoring and dosing of unfractionated heparin. Authors' reply (2004) (1)
Thrombocytopenia is Associated With Increased Binding of IgG to Platelets Both In Vivo and In Vitro (2016) (1)
Is There a Relationship Between the Intensity of Heparin Treatment and Recurrent Thomboembolism? (1997) (1)
The clinical usefulness of platelet-inhibiting drugs in the prevention of cardiac and cerebral events (1985) (1)
ArticlesAspirin and Other Platelet Active Drugs: Relationship Among Dose, Effectiveness, and Side Effects (1989) (1)
Evidence-Based Clinical Practice Guidelines ed: American College of Chest Physicians Therapy and Prevention of Thrombosis, 9th Thrombosis Guidelines : Antithrombotic Antithrombotic Therapy and Prevention of Methodology for the Development of (2012) (1)
A Low-Molecular-Weight Heparinoid Compared with Unfractionated Heparin in the Prevention of Deep Vein Thrombosis in Patients with Acute Ischemic Stroke (2020) (1)
Proceedings: Heparin kinetics in venous thrombosis and pulmonary embolism. (1975) (1)
Subcutaneous or intravenous phytonadione? (1995) (1)
Requirement of Factor VIII for the Generation of Xa in a Purified System and in Plasma. (1979) (1)
Abstract 6048: An Indirect Comparison of the Efficacy and Safety of Factor Xa Inhibitors with Thrombin Inhibitors nn Preventing Venous Thromboembolism after Hip or Knee Surgery (2008) (1)
Suboptimal Monitoring and Dosing of Unfractionated Heparin (2004) (1)
Treatment of first episode of venous thrombosis. (1987) (1)
The effect of plasma proteins and platelet release products on the anti-thrombin activities of standard heparin and dermatan sulfate (1992) (1)
Plasma Rivaroxaban Level to Identify Patients at Risk of Drug Overexposure: Is a Single Measurement of Drug Level Reliable? (2021) (1)
Low-molecular-weight heparin vs. warfarin for prophylaxis against deep-vein thrombosis. (1994) (1)
Incidence of Recurrent Venous Thromboembolism According to Duration of Vitamin K Antagonists: Results of a Meta-Analysis on Individual Data. (2004) (1)
Mortality benefit in the COMPASS trial: is it related to superior statistical power or better efficacy and safety? (2020) (1)
A response to – There's madness in their methods (2013) (1)
Heparin Side Effects-Reply. (1984) (1)
LOW-DOSE HEPARIN PROPHYLAXIS (1976) (1)
Analytic Reviews : Antithrombotic Tberapy in Acute Myocardial Infarction and Unstable Angina (1987) (1)
Clinical Studies with Anticoagulants that Have Changed Clinical Practice (2023) (1)
[Canadian Consensus Conference on Coronary Thrombolysis--current aspects]. (1995) (1)
Antithrombotic Therapy , and Pregnancy : Venous Thromboembolism , Thrombophilia (2008) (1)
Letter by de Vries et al Regarding Article "Off-Label Under- and Overdosing of Direct Oral Anticoagulants in Patients With Atrial Fibrillation: A Meta-Analysis". (2022) (1)
Inflammation as a mechanism and therapeutic target in peripheral artery disease. (2022) (1)
Anticoagulation of the Elderly Patient. (1999) (1)
The Use Of Non-Invasive Testing And Venography For The Diagnosis Of Acute Recurrent Deep Vein Thrombosis (1981) (1)
Thrombosis in Antithrombin-III-deficient Persons (2020) (1)
Abstract of the 12th International Congress on Thrombosis Plenary lectures of the 12th International Congress on Thrombosis Plenary lectures of the 12tLimitations of impedance plethysmography (IPG) in the diagnosis of clinically suspected deep-vein thrombosis (DVT) (1992) (1)
New Anticoagulants Hirudin and Hirulog in the Treatment of Acute Coronary Syndromes (1995) (1)
Randomized trial to examine the effect of ASA dose or ASA dosing frequency on ASA resistance after coronary artery bypass graft surgery (2013) (1)
INR reporting in Canadian medical laboratories (1995) (1)
Aspirin: its effect on platelet glycolysis and release of adenosine diphosphate. (1968) (1)
Infusing Mature Megakaryocytes Into Mice Yields Functional Platelets: Biological and Clinical Implications. (2009) (1)
Across the table. (1982) (1)
ONLY A ROSE (1983) (1)
Low-Molecular-Weight Heparin on Cancellous Bone in Rats A Histomorphometric Comparison of the Effects of Heparin and (2013) (0)
Title Page / Contents / Preface / Contributors (1975) (0)
Platelets, drugs and thrombosis : proceedings of a symposium held at McMaster University, Hamilton, Ont., October 16-18, 1972 (1975) (0)
Prophylaxis of venous thrombosis ( high-risk surgery ) Treatment of venous thrombosis Treatment of pulmonary embolism Prevention of systemic embolism Tissue heart (2002) (0)
The physiological basis of pelvic floor exercises in the treatment of stress urinary incontinence (1999) (0)
Perspectives on the Role of Platelets in Hemostasis and Thrombosis (1984) (0)
Prevention of Deep Vein Thrombosis after Elective Hip Surgery (2020) (0)
37 – Antithrombotic Therapy (2012) (0)
activity in plasma by complementary pathways Heparan sulfate and dermatan sulfate inhibit the generation of thrombin (2011) (0)
The relationship between antithrombin III levels and the anticoagulant effect of standard heparin (1992) (0)
Vitamin K in anticoagulation therapy (2001) (0)
Position of oral anticoagulant therapy among other current antithrombotic treatments (1990) (0)
Review: Factor V Leiden mutation increases risk for thromboembolism (1998) (0)
PROBLEMS WITH THE INTERNATIONAL NORMALIZED RATIO. RESPONSE (1992) (0)
Fibrinopeptide A (FPA) Levels in Venous Thrombosis and Pulmonary Embolism Before and During Anticoagulant Therapy (1977) (0)
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should: • Include no more than 300 words of text, three authors, and five (1999) (0)
Accuracy of I fibrinogen leg scanning for the detection of popliteal and femoral vein thrombosis (1976) (0)
Relative Contributions Of Thrombin And Antithrombin III Affinities Of Heparin Fractions To The Rate Of Inactivation Of Thrombin By Antithrombin III (1981) (0)
Preparation of Human Fibrinogen Free of Plasminogen by Immunoadsorption (1972) (0)
Clinical Impact of Inaccuracies in Anticoagulation Monitoring-Reply (1995) (0)
Anticoagulation and Prothrombin Time Ratios-Reply (1992) (0)
Resolution ofExperimental Pulmonary Emboliwith Heparin andStreptokinase in Different DosageRegimens (1974) (0)
ORGARAN. Extending the Frontiers of Venous Thrombosis Prophylaxis: Satellite Symposium held during the 13th Congress of the International Society of Thrombosis and Haemostasis (ISHT), Amsterdam, July 1991 (1992) (0)
The Mielke bleeding-time. (1973) (0)
The Effects Of Heparin On The Activation Of Factor X And Prothrombin In Antithrombin III-Depleted Plasma (1981) (0)
Logistics of double-blinding a randomized trial of intravenous vs. subcutaneous heparin for the treatment of venous thrombosis (1984) (0)
I FiCREASED 0 I PYRI D,QloLE PLAS!th CONCENTRATIONS AS~OC I ATE0 '~1 I TH 3AL 1 i'r LATE ADBIYISTRATION. RELATIOKSHIP TO EFFECTS ON PLATELET AGGREGATION IN VIvD (1979) (0)
504 Subtle Differences in Commercial Heparins Can Have Serious Consequences for Cardiopulmonary Bypass Patients: a randomized controlled trial (2012) (0)
Platelets. (2020) (0)
Considerations, Monitoring, Efficacy, andSafety (2013) (0)
Venous Return Assist Devices for Intermittent Claudication: A Randomized Controlled Trial Utilizing a Sham Comparator (2019) (0)
A Randomized Trial of Less Intense Postoperative Warfarin or Aspirin Therapy in the Prevention of Venous Thromboembolism After Surgery for Fractured Hip (1990) (0)
Preface (1989) (0)
Blood tests for the diagnosis of venous and arterial thrombosis. (1981) (0)
antithrombotic effectiveness Progress review: the relationship between dose of aspirin, side-effects and (2011) (0)
Low dose heparin prophylaxis in elective surgery: A randomized study (1974) (0)
Clinical use of coronary thrombolytic therapy. Contraindications. (1993) (0)
Estimated risk of deep venous thrombosis among Chinese patients admitted to general medical wards (2004) (0)
Untitled (2017) (0)
Streptokinase in acute major pulmonary embolism. (1969) (0)
Impedance Plethysmography for Suspected Deep-Vein Thrombosis-Reply (1995) (0)
Chapter 61. Venous Thromboembolic Disease (2007) (0)
Antithrombotic agents in coronary artery disease. (1986) (0)
Glycolysis and Oxidative Metabolism Energy Metabolism in Human Platelets:Interrelationship Between (2011) (0)
The effects of a free fatty acid preparation of omega-3 polyunsaturated fatty acids on platelet function alone and in combination with aspirin and low molecular weight heparin (1991) (0)
The (Variable) Definition of Benefit in the Case of Clopidogrel vs Aspirin—Reply (2005) (0)
HEPARIN IS NOT AN EFFICIENT INHIBITOR OF THE FACTOR Xa-DEPENDENT ACTIVATION OF FACTOR V AND FACTOR VIII (1987) (0)
This large well-conducted study provides the clinician with (2017) (0)
INR reporting in Canadian medical laboratories. Thrombosis Interest Group of Canada. (1995) (0)
New Antithrombotics for the Treatment of Acute and Chronic Arterial Ischemia (1996) (0)
Assessment of antithrombotic drugs ex vivo and in vivo. (1977) (0)
Title Page / Table of Contents, Vol. 26, Supplement 4, 1996 (1996) (0)
Effectiveness of Coumadin for Secondary Prophylaxis in Patients with Established Venous Thrombosis(DVT) (1979) (0)
Shifting the Focus of Medical Research From the Bench to the Bedside (2017) (0)
MONITORING HEPARIN THERAPY. AUTHORS' REPLY (1994) (0)
Author Index / Subject Index, Vol. 25, 1995 (1995) (0)
in Association With a Monoclonal Gammopathy Von Willebrand's Syndrome Presenting as an Acquired Bleeding Disorder (2011) (0)
The additive effect of dermatan sulfate and low molecular weight heparins on thrombin inhibition in vitro (1992) (0)
Venous thromboembolism in surgery : a risk to be prevented, September 10, 1990, Montreal (1991) (0)
IMPEDANCE PLETHYSMOGRAPHY FOR SUSPECTED DEEP-VEIN THROMBOSIS. AUTHORS' REPLY (1995) (0)
Guidelines for anticoagulant use in acute coronary syndromes – Authors' reply (2008) (0)
Differential Diagnosis of Symptoms and Signs of Venous Thrombosis (2010) (0)
Hemorrhagic Complications of Thrombolytic Therapy inthe Treatment ofMyocardial (2017) (0)
Antithrombotic Effect of Sulfinpyrazone in Arterio-venous Shunts (1975) (0)
TheRelationship AmongDose, Effectiveness, andSideEffects (2017) (0)
to the Antithrombotic Effects of Heparin (2016) (0)
than that of red cells labeled with "Tc even in the control State. This is just the opposite of data reported by us (1982) (0)
THROMBOSIS IN ANTITHROMBIN-III DEFICIENCY. REPLY (1992) (0)
[Anticoagulants and other drugs effective against thrombosis]. (1978) (0)
Thromboembolism and Haemostasis Programme (1972) (0)
The hemodynamic response to isoproterenol in massive acute pulmonary embolism. (1969) (0)
Review: extended out-of-hospital prophylaxis with heparin prevents deep venous thrombosis in elective hip arthroplasty. (2002) (0)
Laboratory monitoring of oral anticoagulant therapy. (1989) (0)
cardiopulmonary bypass in a pig model Antithrombin-heparin covalent complex reduces microemboli during (2013) (0)
Sex Related Differences in Platelet Function : The Effect of Aspirin Blood (2005) (0)
Impedance Plethysmography and DVT Diagnosis (1993) (0)
[Prevention of deep vein thrombosis and pulmonary thromboembolism]. (1981) (0)
Consultation and guidelines reduced anticoagulant-related bleeding in high-risk patients (1992) (0)
The Influence Of Heparin, Phospholipid And Platelets On The Thrombin Or Factor Xa Inactivation By Antithrombin III (1981) (0)
Antivitamines K : Mécanisme d'action, efficacité clinique et zone thérapeutique optimale (2000) (0)
Evidence that vitronectin contributes to non-specific binding of heparin in patient plasma (1997) (0)
Addiction-prevention drug formulations (2005) (0)
Significance: Clinical or Statistical?-Rebuttal (1989) (0)
Streptokinase Therapy inAcuteMajorPulmonary Embolism: Effectiveness andProblems (1968) (0)
Heparin Kinetics in venons Thrombosis and Pulmonary Embolism (1975) (0)
Formulations de prevention des abus (2005) (0)
experimental pulmonary embolism Mechanisms for elevated fibrin/fibrinogen degradation products in acute (2011) (0)
Hirsh and Fuster Guide to Anticoagulant Therapy : Part 1 TABLE 1 . Antihemostatic Effects of Heparin Effect Comment Binds to (2005) (0)
The Biphasic Effect of Sulfinpyrazone on Platelet Function (1977) (0)
The multiple faces of the partial thromboplastin time APTT (2004) (0)
Efficacy and Monitoring of Heparin Therapy in Experimental Venous Thrombosis (1975) (0)
Method and device for the prediction of cardiovascular events (2003) (0)
Evaluation of av enous-return assis td evic et ot reat severe post-thromboti cs yndrome (VENOPTS) (2008) (0)
Vena cava filters reduced long-term risk for pulmonary embolism in proximal deep venous thrombosis. (2006) (0)
Subcutaneous compared with intravenous heparin for deep vein thrombosis. (1992) (0)
ORAL ANTICOAGULANTS. AUTHOR'S REPLY (1994) (0)
Action Spectrum and Structural Changes Induction of Aggregation of Human Blood Platelets by Ultraviolet Light (2011) (0)
low molecular weight heparin in rabbits The relationship between the hemorrhagic and antithrombotic properties of (2011) (0)
Elevated Platelet Antibodies in Septicemic Thrombocytopenia (1979) (0)
venous thrombosis Clinical validity of a negative venogram in patients with clinically suspected (2011) (0)
The Effect of a Combination of Sulfinpyrazone (SUL) & Aspirin (ASA) on Platelet Survival & Thrombus Size in an Experimental Thrombosis Model (1977) (0)
clinically suspected deep vein thrombosis The diagnostic value of the fibrinogen/fibrin fragment E antigen assay in (2011) (0)
Formulations for drug abuse prevention (2005) (0)
Diagnosis Of Deep Vein Thrombosis - “The Case for NonInvasive Testing” (1981) (0)
UTILITY OF IMPEDANCE PLETHYSMOGRAPHY IN CHILDREN WITH CLINICALLY SUSPECTED VENOUS THROMBOEMBOLIC DISEASE (1987) (0)
[Diagnosis of deep vein thrombosis by invasive and non invasive methods]. (1980) (0)
Randomized Clinical Trial Of Titrated Dose Subcutaneous Heparin Versus Warfarin In The Long-Term Treatment Of Patients With Venous Thrombosis (1981) (0)
Compositions a liberation intermittente de milnaciprane (2003) (0)
Pathogenesis of Venous Thromboembolism (2016) (0)
The diagnosis and prevention of post operative venous thrombosis. (1973) (0)
Antithrombotic drugs: III (1976) (0)
Preparations stabilisees de bupropion pour administration par voie transdermique (2007) (0)
[Diagnosis of venous thrombo--emboli]. (1978) (0)
Vasoactive Substances in Pulmonary Embolism (1977) (0)
Variety of perspectives: Controversies in the Management of Venous Disorders: Scandinavian Contributions on Venous Problems with Comments by International Authorities. (1990) (0)
Lidocaine and the reduction of post-venographic pain. (1984) (0)
Erratum to: Relation between clopidogrel active metabolite levels and different platelet aggregation methods in patients receiving clopidogrel and aspirin (2012) (0)
Communications to the EditorOral Anticoagulant Therapy Recommendations (1994) (0)
Oral Anticoagulant Therapy (1994) (0)
Compression ultrasonography detected proximal deep venous thrombosis but not isolated iliac and calf deep venous thrombosis (1992) (0)
Abstract 5795: Impact of the Modified Henry Ford Warfarin Maintenance Dosing Algorithm on Quality of Anticoagulation at a Specialist Anticoagulation Clinic (2009) (0)
Oral Anticoagulants-To the Editor (1994) (0)
[Treatment of venous thrombo--emboli]. (1978) (0)
Monitoring Heparin Therapy (1994) (0)
Comments, Opinions, and Reviews Hemorrhagic Complications of Long-Term Anticoagulant Therapy for Ischemic Cerebral Vascular Disease (1986) (0)
The impact of clinical research on clinical practice (2020) (0)
Faster Through the Cerebral Microcirculatory System, Red Cells or Plasma? (2008) (0)
After Aspirin Relation Between Bleeding Time and Platelet Connective Tissue Reaction (2011) (0)
Low-Molecular-Weight Heparin Should Replace Unfractionated Heparin for Treatment of Venous Thrombosis and Unstable Angina (2004) (0)
Thrombolytic therapy and fatal pulmonary emboli. (1971) (0)
Clinical utility of impedance plethysmography in the diagnosis of recurrent deep-vein thrombosis. (1988) (0)
Zinc-levamisole combination: Powerful synergistic immunopotentiation? (2005) (0)
Scope of the Problem (2017) (0)
[Venous thromboemboli]. (1978) (0)
Small dose subcutaneous heparin in preventing deep venous thrombosis (1975) (0)
Antihemophilic globulin (AHG) response to exercise for the detection of hemophilia A carriers (1971) (0)
The Diagnosis Of Pulmonary Embolism: The Diagnostic Dilemma Of Ventilation-Perfusion Lung Scanning (1981) (0)
Degradation Products in Acute Experimental Pulmonary Embolism (2017) (0)
Guidelines for antithrombotic therapy: summary of the American College of Chest Physicians recommendations 2000 (2017) (0)

This paper list is powered by the following services:

Other Resources About Jack Hirsh

en.wikipedia.org

What Schools Are Affiliated With Jack Hirsh?

Jack Hirsh is affiliated with the following schools:

Jack Hirsh's Academic­Influence.com Rankings

Jack Hirsh's Degrees

Why Is Jack Hirsh Influential?

Jack Hirsh's Published Works

Published Works

Other Resources About Jack Hirsh

What Schools Are Affiliated With Jack Hirsh?

Jack Hirsh's AcademicInfluence.com Rankings